Premium
Florbetapir ( 18 F) for brain amyloid positron emission tomography: Highlights on the European marketing approval
Author(s) -
CortesBlanco Anabel,
PrietoYerro Concha,
MartinezLazaro Raul,
Zamora Javier,
JiménezHuete Adolfo,
Haberkamp Marion,
Pohly Johannes,
Enzmann Harald,
Zinserling Jörg,
Strassmann Valerie,
Broich Karl
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.09.007
Subject(s) - positron emission tomography , cognitive impairment , authorization , amyloid (mycology) , medicine , senile plaques , neuroimaging , cognition , psychology , alzheimer's disease , disease , neuroscience , nuclear medicine , pathology , psychiatry , computer science , computer security
Florbetapir ( 18 F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β‐amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir ( 18 F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir ( 18 F).